Moleculin Biotech Inc opened higher at $8.77, compared with its previous close of $8.10. In the last trading session, the stock traded between $8.03 and $8.90. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Moleculin Biotech Inc is now worth
$ 0.86
Resulting in a loss of
$ 99.14 (99.14%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.11 (+1.35%)
Day High
$8.90
Day Low
$8.03
Day Open
$8.77
Prev Close
$8.10
Volume
41,086
1W Return
-2.64%
1M Return
1,897.32%
3M Return
1,795.84%
6M Return
236.43%
1Y Return
-31.43%
Fundamentals
Market Cap ($ Mn)
9
PE Ratio
0.07
PB Ratio
0.39
PEG Ratio
-
ROE
-
ROCE
-242.87%
EPS (TTM)
$-22.43
Investment Returns
1 Week
-2.64%
1 Month
1,897.32%
3 Months
1,795.84%
6 Months
236.43%
9 Months
96.39%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
12Nov
Moleculin Biotech secures Australian patent for Annamycin formulation
Moleculin Biotech and UT System granted Australian Patent No. 2020303572 for Annamycin formulation. The patent covers the preparation of preliposomal Annamycin lyophilizate, a key aspect of its formulation technology. Global IP portfolio now includes granted or allowed patents in 10 jurisdictions, including US, Europe, and China. Additional patents pending in South Africa (accepted) and South Korea (application pending).
Today
11Nov
Moleculin Biotech Annamycin combo extends survival in pancreatic cancer models
Annamycin combined with PD-1 blockade extended survival in pancreatic cancer models beyond either agent alone. The drug achieves substantially higher and more sustained exposure in pancreatic tissue than doxorubicin. Inhibition of CD8+ T cells shortened survival, proving immune cells are functional contributors to antitumor activity. Data supports evaluating Annamycin in combination with approved PD-1 inhibitors for immunologically cold tumors.
2 days ago
4Nov
Moleculin Biotech Annamycin data accepted for ASH 2026 annual meeting
Interim data shows 43% and 36% complete remission rates in Annamycin arms versus 12% in placebo. No signs of cardiotoxicity observed through the data cutoff period. Abstract accepted for poster presentation at the December 2026 ASH Annual Meeting.
